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INTRODUCTION
The aging process is associated with the loss of muscle 
mass, resulting in a loss of muscle strength and func-
tion that has been referred to as sarcopenia 1 2. Sarco-
penia as a geriatric syndrome leads to the limitation of 
physical performance and increases the risk of adverse 
outcomes including mobility limitation, disability, hospi-
talization, low quality of life, and death 3 4.
In 2014 the International Sarcopenia Initiative pub-
lished a systematic review 5 reporting the prevalence of 
sarcopenia estimated by several studies performed in 
various geriatric settings: if assessed according to Eu-
ropean Working Group on Sarcopenia in Older People 
(EWGSOP) criteria  4, the prevalence of sarcopenia in 
community-dwelling populations ranges from 1 to 29%; 
the prevalence of sarcopenia is even more substantial 
in institutionalized populations: from 14 to 68% among 
male subjects and from 14 to 33% among female sub-
jects.
Recently, the Foundation for the National Institutes of 
Health (FNIH) Sarcopenia Project has proposed new 
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diagnostic criteria for the assessment of sarcopenia 
based on the analysis of 9 population studies con-
ducted on a 26625 community-dwelling older adults 6, 
assessing the role of weakness (defined as low muscle 
strength) and low muscle mass as key components of 
the sarcopenia phenotype.
Despite sarcopenia has been found to be an extremely 
common condition among institutionalized older peo-
ple 7 8, currently the amount of data regarding this geri-
atric setting is relatively scarce, due to the difficulties of-
ten encountered while analyzing this population 7: first, 
institutionalized subjects are often affected by several 
medical conditions and cognitive impairment, which 
may hinder the reliability of some diagnostic tests; sec-
ond, Dual-Energy X-ray Absorptiometry (DXA), which is 
the reference technique for the assessment of muscular 
mass, and bioimpendance analysis (BIA), an easily ac-
cessible and portable DXA alternative 9, are not usually 
available in nursing homes.
The estimated prevalence of sarcopenia among differ-
ent studies performed on institutionalized populations is 
extremely heterogeneous due to the lack of a common 
consensus regarding the diagnostic criteria and the 
methods used to assess sarcopenia criteria (muscle 
mass, muscle strength and physical performance). The 
majority of the studies performed on institutionalized 
populations assessed sarcopenia according to EWG-
SOP criteria, whereas studies on prevalence of sarco-
penia according to the FNIH diagnostic criteria are still 
lacking in this population.
This study was designed to investigate the prevalence 
and clinical correlates of sarcopenia in older institution-
alized adults in Italy, and to compare the data obtained 
using two different definitions of sarcopenia, the EW-
GSOP and FNIH criteria. We investigated the inter-
changeability and the discrepancies between the two 
definitions; we also evaluated the adequacy of the cur-
rent diagnostics criteria when applied to a population 




This cross-sectional study was performed on the 
residents of “Centro Servizi Anziani di Monselice”, a 
structure that is both a Retirement and Nursing Home, 
located in Monselice, Veneto, Italy.
As of April 2017, the structure hosted a total of 158 
older people.
Participants’ data were collected through the consulta-
tion of the medical records provided by the structure 
and a standardized dedicated questionnaire including 
demographic characteristics, functional status, cogni-
tive status, mood assessment, medication use and 
incident and prevalent medical conditions.
Exclusion criteria were: inability to undergo BIA (leg 
edema, pacemaker, joint prosthesis, bedridden, re-
fused); inability to perform the grip strength test (joint 
prosthesis, severe pain to the upper limbs, refused); 
severe cognitive impairment which precluded the com-
plete cooperation during the questionnaire filling or the 
tests execution; inability or refusal to grant approval for 
the inclusion in this study; new entries with inadequate 
anamnestic and clinical documentation.
Prevalence of sarcopenia and of its clinical correlates 
was therefore assessed in 97 subjects, 26 males and 
71 females. 
aSSeSSment of Sarcopenia
According to EWGSOP 4 criteria, sarcopenia was de-
fined as presence of low muscle mass plus low muscle 
strength and/or low walking speed. As requested by 
FNIH criteria  6, sarcopenia was defined as “weakness 
and low lean mass” or “slowness with weakness and 
low lean mass”.
Muscle mass was measured by BIA using a Quantum/S 
Bioelectrical Body Composition Analyzer (Akern Srl, 
Florence, Italy). Whole-body BIA measurements were 
taken between the right wrist and ankle with the subject 
in a supine position, when possible. Appendicular Lean 
Mass (ALM) was calculated using the following equa-
tion of Scafoglieri and colleagues 10: ALMHOLOGIC(kg) = 4, 
957 + (0, 196 X height2/resistance) + (0.060 X weight) - 
(2.554 X sex), where height is measured in centimeters; 
resistance is measured in ohms; weight is measured 
in kilograms; for gender, men  =  0 and women  =  1. 
Appendicular lean mass (kg) was converted to appen-
dicular skeletal muscle index (ASMI) standardizing by 
meters squared (ALM/height2) and Body Mass Index 
(ALM/BMI) as requested by EWGSOP and FNIH criteria 
respectively. As claimed by EWGSOP criteria 4, low ap-
pendicular muscle mass was classified as ASMI less 
than 7.23 kg/m2 in men and 5.67 kg/m2 in women; ac-
cording to FNIH 6, low appendicular muscle mass was 
classified as a ALM/BMI ratio lower than 0.789 and 
0.512 in men and women, respectively.
Muscle strength was assessed by grip strength (GS), 
measured using a hand-held dynamometer (JAMAR 
hand dynamometer, Sammons Preston Inc, Boling-
brook, Illinois, USA). Two trials with the dominant 
hand were performed, when possible, and the highest 
value was used in the analysis  11. According to EW-
GSOP  4  12, Body mass index (BMI) - adjusted values 
were used as a cutoff point to identify low muscle 
strength (men: BMI ≤ 24 kg/m2 GS ≤ 29 kg, BMI 24.1-
28 kg/m2 GS ≤ 30 kg, BMI ≥ 28 kg/m2 GS ≤ 32 kg; 
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women: BMI ≤ 23 kg/m2 GS ≤ 17 kg, BMI 23.1-26 kg/
m2 GS  ≤  17.3  kg, BMI 26.1-29  kg/m2 GS  ≤  18  kg, 
BMI ≥ 29 kg/m2 GS ≤ 21 kg) while, in line with FNIH 
criteria  6, crude values were used (men: GS < 26 kg; 
women: GS < 16 kg). 
Usual walking speed (m/s) on a 4-m course was used 
as an objective measure of physical performance; speed 
lower than 0.8 m/s identified participants with low physi-
cal performance (“slow walkers”) 4 6. Thirty-seven sub-
jects did not perform the walking test; since all of them 
were unable to walk or had an extremely high risk of fall, 
we included them among those who performed the test 
and were classified as “slow walkers”. Since more than 
97% of the subjects (94 out of 97) resulted “slow walk-
ers”, we decided to ignore the walking speed criterion 
included in both sarcopenia definitions; this decision was 
supported by the result of a previous study 12 suggesting 
that low walking speed might not be an essential crite-
rion for the diagnosis of sarcopenia.
covariateS
Sociodemographic characteristics. Sociodemographic 
variables (Age, gender, smoking habit, alcohol con-
sumption, education) were assessed through survey 
questions. 
Functional and mobility status. Functional status in 
basic activities of daily living (ADLs) and mobility were 
assessed trough a modified Barthel Index (BI) 13, which 
has been adapted to be paired with S.Va.M.A score for 
the evaluation of the elderly in institutionalized settings. 
Functional status in basic ADL was measured accord-
ing to the participants’ difficulty in performing each of six 
activities: getting in and out of a bed, bathing, dressing, 
eating, continence, and using the toilet. The score for 
functional status ranges between 0 (independent) and 
60 (dependent); a score ≥ 15 identified functional dis-
ability, whereas a score ≥ 50 identified severe functional 
disability. Mobility status was measured according to 
the participants’ difficulty in performing each of five 
tasks: walking, wheelchair use, moving from bed-chair 
to wheelchair, going up and down stairs. The score for 
functional status ranges between 0 (independent) and 
40 (dependent); a score ≥ 15 identified mobility impair-
ment, whereas a score ≥ 30 identified severe mobility 
impairment.
Cognitive and mood status. Cognitive functioning was 
explored using the Mini Mental State Examination 
(MMSE), with scores less than 24 suggesting cognitive 
impairment. Mood status was assessed with the 15 
item version of the Geriatric Depression Scale (GDS), 
with scores more than 5 out of 15 suggesting the pres-
ence of depressive symptoms 14.
Specific medical conditions and comorbidity. The 
baseline prevalence of specific medical conditions was 
established using standardized criteria that utilized in-
formation gathered from the structure’s clinical records. 
Comorbidity levels were assessed using the Cumulative 
Illness Rating Scale (CIRS) calculating for each partici-
pants CIRS severity index and CIRS comorbidity index 15.
StatiStical analySiS
For descriptive purpose, baseline characteristics of 
the study population were compared according to 
presence or absence of sarcopenia, using a t-student 
test for continuous variables with normal distribution, 
the nonparametric Wilcoxon Mann-Witney test for 
not normally distributed continuous variables and the 
Fisher-exact test for categorical variables. To identify 
factors independently associated with the two sarco-
penia phenotype we utilized univariate logistic regres-
sion analysis; factors resulted independently related to 
sarcopenia was then included in multivariate logistic 
regression models for each sarcopenia definition.
All analyses were performed using Stata 13.0 for Win-
dows (StataCorp, College Station, TX). 
RESULTS
General characteristic of 97 participants (mean age 
83.2 ± 9.4, 73.2% women) according to the presence 
of sarcopenia are presented in Table I.
13 (13.4%) participants were identified as sarcopenic 
using each sarcopenia criteria separately; between 
them, only 5 subjects were simultaneously identified as 
sarcopenic according to both definitions (Fig. 1). 
Sarcopenic participants were more likely to be male 
(Fig. 2): 26.9% and 30.8% of the male participants were 
identified as sarcopenic according to EWGSOP and 
FNIH criteria respectively, while only 8.5% (EWGSOP) 
and 7% (FNIH) of the female subjects were identified 
as sarcopenic. Prevalence of sarcopenia increased 
in subjects included in the 80-89 years range (18.8% 
EWGSOP, 21.9% FNIH) compared to younger subjects 
(13.5% EWGSOP, 8.1% FNIH); lower sarcopenia preva-
lence was conversely found in subjects 90 years old or 
older (7.1% EWGSOP, 10.7% FNIH) (data not shown). 
No significant difference was found between sarcopenic 
and not sarcopenic participants, defined by EWGSOP 
criteria, in both severe functional disability and severe 
mobility impairment prevalence; conversely we found 
a substantial although not statistically significant differ-
ence in severe functional disability when sarcopenia was 
defined according to FNIH criteria (46.2% and 23.8% in 
sarcopenic and not sarcopenic participant respectively). 
Figure 3 shows BMI distribution in sarcopenic subjects: 
the vast majority of sarcopenic subjects, independently 
by the sarcopenia definition used, were included in the 
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21-29kg/m2 BMI range (84.6% EWGSOP, 92.3% FNIH). 
Taking into account EWGSOP criteria, 15.4% of the 
sarcopenic subjects had BMI lower than 21kg/m2, while 
none of them could be defined as obese (BMI > 30 kg/
m2); conversely, according to FNIH criteria, none of the 
sarcopenic subjects had BMI lower than 21kg/m2, while 
7.7% of them had BMI > 30kg/m2.
No difference was found in prevalence of cognitive 
impairment between sarcopenic and not sarcopenic 
subject identified by EWGSOP definition. Conversely, 




PNo Sarcopenia Sarcopenia No sarcopenia Sarcopenia
N 84 (86.6%) 13 (13.4%) 0.612 84 (86.6%) 13 (13.4%) 0.782
Male (%) 22.6 53.8 0.018 21.4 61.5 0.002
Age (years) 83.3 ± 9.9 82 ± 6.1 0.508 83.0 ± 9.7 84.5 ± 7.5 0.597













BMI (kg/m2) 27.9 ± 4.5 23.1 ± 3.2 0.001 27.2 ± 4.9 27.7 ± 2.2 0.502
Weight loss ( ≥ 10% in the last 
6 months) 
16.7 23.1 0.572 16.7 23.1 0.572
ASMI (kg/m2) 6.7 ± 0.9 6.0 ± 0.7 0.009 6.5 ± 0.9 6.8 ± 0.77 0.424
ALM/BMI 0.6 ± 0.1 0.7 ± 0.1 0.020 0.6 ± 0.1 0.6 ± 0.1 0.723
Grip strength (kg)          22.1 ± 7.8 17.8 ± 4.6 0.009 22.1 ± 7.8 17.7 ± 4.8 0.009
4-m walking speed
(n = 60, m/s) 
0.5 ± 0.2 0.4 ± 0.1 0.214 0.5 ± 0.2 0.5 ± 0.1 0.623
Severe functional disability (%) 26.2 30.8 0.742 23.8 46.2 0.103
Severe mobility impairment (%) 36.9 30.8 0.765 35.7 38.5 1.000
CIRS severity (median, IQR) 1.3 [1-1.5] 1.4 [1-1.6] 0.391 1.3 [1-1.5] 1.5 [1-1.6] 0.402
CIRS comorbidity (median, IQR) 2 [1-3.5] 4 [1-4] 0.167 2 [1-3.5] 4 [2-4] 0.044
Cognitive impairment
(n = 95, %) 
60.2 58.3 0.900 57.3 76.9 0.180
Number of medications 6.5 ± 3.0 5.9 ± 2.2 0.232 6.5 ± 3.0 5.8 ± 2.2 0.412
BMI = body mass index; ASMI = appendicular skeletal muscle index; ALM = appendicular lean mass; CIRS = cumulative illness rating scale; IQR = interquartile range.
Data are means ± SD unless otherwise indicated.
Figure 1. Prevalence of sarcopenia according to sarcopenia 
definition. Individually, both EWGSOP and FNIH criteria identified 
13 participants as sarcopenic; only 5 subjects were identified as 
sarcopenic according to both definitions simultaneously.
Figure 2. Prevalence of sarcopenia according to sex and de-
finition of sarcopenia. Both EWGSOP and FNIH criteria found 
the prevalence of sarcopenia to be substantially higher in male 
subjects compared to female subjects.
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according to FNIH criteria cognitive impairment tend 
to be more common in sarcopenic subject (76.9% and 
57.3% for sarcopenic and not sarcopenic participants 
respectively). 
The average number of medications assumed was found 
to be marginally lower in the sarcopenic subjects com-
pared to not sarcopenic subjects using both definition.
In univariate logistic regression analysis male sex was 
significantly associated with sarcopenia prevalence 
using both sarcopenia definition (OR:12.14; 95% CI: 
2.31-63.67 for EWGSOP and OR:5.52; 95% CI: 1.54-
19.88 for FNIH criteria). Considering EWGSOP criteria, 
we found a decreased probability of being sarcopenic 
with increasing BMI (OR: 0.64; 95% CI: 0.50-0.82). Ac-
cording to FNIH definition, subjects with higher CIRS 
comorbidity score were more likely to be sarcopenic 
(OR: 1.48; 95% CI: 1.02-2.16). Using the same criteria, 
an increased probability of being sarcopenic was also 
found for participants with severe functional disability 
although this relationship was of borderline statistical 
significance (OR 2.74; 95% CI: 0.83-9.11) (Tab. II). 
Multivariable analysis confirmed an independent and 
significant association between male sex and sarcope-
nia defined according to both criteria (OR 95% 12.1; 
95%CI 2.3-63.7 for EWGSOP and OR 5.52; 95% CI 
1.54-19.9 for FNIH). Inverse association between BMI 
and probability of being sarcopenic (EWGSOP defini-
tion) was also confirmed (OR 0.64; 95% CI 0.50-0.82) 
as well as an increased risk of being sarcopenic (FNIH 
definition) with higher CIRS comorbidity score (OR 1.48; 
95% CI 1.02-2.16). 
DISCUSSION
Our study suggest that, among a population of institu-
tionalized older people, sarcopenia, defined by either 
EWGSOP or FNIH criteria, is a common condition. Male 
sex was significantly associated with sarcopenia using 
both definition; higher BMI was inversely associated 
with sarcopenia prevalence defined by EWGSOP crite-
ria whereas level of comorbidity was directly associated 
with sarcopenia defined according to FNIH criteria.
The estimated prevalence of sarcopenia from this study 
is in line, although somehow lower, with the values re-
ported in the 2014 International Sarcopenia Initiative re-
view 5, according to which the prevalence of sarcopenia 
in institutionalized older people ranges between 14 and 
33%; however, other studies 7 8 reported a significantly 
higher prevalence of sarcopenia in nursing home set-
tings (as high as 40%). Difference between our data 
and previous report may be justified by the changes we 
applied to the diagnostic criteria of sarcopenia. First, 
we decided to assess muscle mass utilizing the Ap-
pendicular Skeletal Muscle Mass Index, as opposed 
to the Skeletal Muscle Mass Index, since Appendicular 
Lean Mass has been found to be the more specific in 
evaluating the skeletal muscle mass of the elderly 6 16. 
Second, we ignored the walking speed criterion since 
37% of the participants were not able to perform the 
4-m walking test because of the inability to walk or co-
existing medical conditions that contraindicated the test 
administration, and 97% of the study subjects resulted 
“slow walkers”, hindering the effectiveness of walking 
speed as a diagnostic criterion. Our decision was cor-
roborated by the results of a previous study 12 which re-
ported that the assessment of only muscle weakness in 
addition to low muscle mass provided similar predictive 
value compared to the original algorithm of the EWG-
SOP sarcopenia definition in terms of incident disability, 
risk of hospitalization and mortality, suggesting that low 
walking speed might not be an essential criterion for the 
diagnosis of sarcopenia.
In agreement with previous reports in similar settings 7 8, 
our findings suggest that sarcopenia is significantly 
more common among men compared to women.
According to EWGSOP criteria, increasing BMI was in-
versely related to sarcopenia presence and, in our sam-
ple, 15% of sarcopenic subjects were malnourished. On 
the other hand, FNIH criteria led us to opposite findings, 
since no sarcopenic subject was malnourished, but 7.7% 
of them were obese. This significant gap can be justified 
by the different method used to assess low muscle mass 
by the two definitions of sarcopenia: EWGSOP suggests 
to standardize ALM by meters squared while FNIH 
suggests to standardize ALM by Body Mass Index. As 
reported by Dam et al. 6 sarcopenic subjects identified by 
Figure 3. Body Mass Index (BMI) ranges distribution in sarco-
penic subjects. Most of the sarcopenic subjects fall into the 21-
29 BMI range. None of the subjects identified as sarcopenic by 
EWGSOP criteria is obese, while none of the subjects identified 
as sarcopenic by FNIH criteria is malnourished.
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EWGSOP criteria have lower obesity prevalence compa-
red to those identified with FNIH criteria; furthermore the 
FNIH criteria identified participants that, despite having 
higher lean mass and higher BMI, are functionally more 
impaired. These data suggest that the use of lean mass 
adjusted by body mass seems to be the best choice to 
capture subjects that are unable to generate enough 
muscular strength or to achieve an adequate physical 
performance relative to their body mass and that ALM/
BMI may be a good measure for low muscle quality or 
efficiency 6 17.
These results suggest that the EGWOSP and FNIH 
criteria identify as sarcopenic different individuals and 
therefore the two definitions cannot be used inter-
changeably. Since more than one out of five subjects 
of this study were found to be obese, we can assume 
that the results obtained according to FNIH sarcopenia 
definition may offer a better representation of the actual 
sarcopenia prevalence in this population. Furthermore, 
FNIH definition seems to identify a sarcopenia pheno-
type with higher comorbidity level and functional dis-
ability. Nevertheless, longitudinal studies should be per-
formed to directly compare the predictive value in term 
of clinical outcomes of the two diagnostic algorithm.
In interpreting our findings, some limitations should be 
considered. First, the setting limited generalization of 
our findings: the high prevalence of functional impair-
ment along the low cooperation offered from subjects 
with cognitive impairment may have partially compro-
mised the usefulness of the result obtained from the 
gait speed and grip strength tests, as stated before in 
literature with similar population 7. Second, of the 158 
residents, only 97 were included in this study; the ma-
jority of the excluded residents presented health-related 
conditions: healthy selection bias has to be taken into 
account and therefore our analyses might have under-
estimated the true prevalence of sarcopenia. Third, 
the cross-sectional design of the study did not allow 
us to clarify any temporal or cause-effect relationship 
between sarcopenia and its associated factors. Fourth, 
the low number of subject defined as sarcopenic (13 
according to both definitions) might have limited the sta-
tistical significance of the multivariate analyses. Finally, 
the use of BIA for muscle mass assessment presents 
some drawbacks mainly due to the hydration problems 
usually observed in older persons, that may result in an 
underestimation of the body fat and an overestimation 
of fat-free mass. On the other hand, BIA is inexpensive, 
easy to use, readily reproducible, and appropriate for 
both ambulatory and bedridden patients, considered 
as a portable alternative to dual-energy X-ray absorp-
tiometry 9, and its standardized use may favor a wide-
spread assessment of body composition in everyday 
clinical practice and in nursing home residency.
In summary, in this sample of Italian institutionalized 
older people, both EWGSOP and FNIH criteria identify 
Table II. Univariate and multivariate logistic regression analyses for the likelihood of being sarcopenic according to sarcopenia 
definition.
EWGSOP FNIH
Univariate Multivariate Univariate Multivariate
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Sex (male) 3.99 (1.20-23.31) 0.024 12.1 (2.3-63-7) 0.003 5.9 (1.71-20.13) 0.005 5.52 (1.54-19.9) 0.009
Age (years) 0.99 (0.93-1.05) 0.631 1.02 (0.95-1.09) 0.593
Education 
( ≥ 5 years) 
1.58 (0.40-6.21) 0.513 0.47 (0.14-1.53) 0.209
Smokers 1.91 (0.58-6.25) 0.283 1.91 (0.58-6.25) 0.283
BMI (kg/m2) 0.72 (0.60-0.88) 0.001 0.64 (0.50-0.82) < 0.001 1.03 (0.91-1.16) 0.689
Weight loss 
(last 6 months) 
1.50 (0.37-6.16) 0.574 1.50 (0.37-6.16) 0.574
Severe Functional 
Disability (%) 
1.25 (0.35-4.48) 0.729 2.74 (0.83-9.11) 0.099
Severe Mobility 
Impairment (%) 
0.76 (0.22-2.67) 0.669 1.13 (0.34-3.75) 0.848
CIRS severity 1.79 (0.43-7.48) 0.421 1.71 (0.41-7.08) 0.458
CIRS comorbidity 1.31 (0.93-1.85) 0.127 1.54 (1.07-2.21) 0.019 1.48 (1.02-2.16) 0.039
Cognitive impairment 
(n = 95, %) 
0.92 (0.27-3.16) 0.900 2.48 (0.64-9.69) 0.191
Number of 
medications
0.92 (0.75-1.14) 0.461 0.91 (0.73-1.14) 0.408
OR = odds ratio; CI = confidence interval; BMI = body mass index; CIRS = cumulative illness rating scale.
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sarcopenia as a common condition, strongly related to 
male sex, BMI and comorbidity level. Our results sug-
gest that the EGWOSP and FNIH criteria cannot be 
used interchangeably, since both definition identified as 
sarcopenic different individuals. Finally, this study rein-
force the notion that walking speed assessment might 
not be feasible in most of the patients admitted in nurs-
ing home facilities.
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